BioCentury
ARTICLE | Company News

Advanced Cancer Therapeutics, University of Louisville deal

March 10, 2008 7:00 AM UTC

Advanced Cancer Therapeutics received an exclusive, worldwide license from the university to develop and market 3PO and related compounds to treat cancer. The inhibitor of 6-phosphofructo-2-kinase/fru...